

Kim Blom

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4926627/kim-blom-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

291
citations

8
h-index

17
g-index

18
ext. papers

421
ext. citations

6.1
avg, IF

2.79
L-index

#	Paper	IF	Citations
16	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.. <i>Vaccines</i> , 2022 , 10,	5.3	1
15	Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.. <i>Clinical and Translational Immunology</i> , 2022 , 11, e1388	6.8	2
14	Divergent clonal differentiation trajectories establish CD8 memory T cell heterogeneity during acute viral infections in humans. <i>Cell Reports</i> , 2021 , 35, 109174	10.6	3
13	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1306	6.8	16
12	Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination. <i>Journal of Immunology</i> , 2021 , 207, 1033-1043	5.3	4
11	Magnitude and Functional Profile of the Human CD4 T Cell Response throughout Primary Immunization with Tick-Borne Encephalitis Virus Vaccine. <i>Journal of Immunology</i> , 2020 , 204, 914-922	5.3	2
10	Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. <i>Journal of Immunology</i> , 2020 , 205, 2437-2446	5.3	48
9	Effectiveness of the herpes zoster vaccine Zostavax [®] in Stockholm County, Sweden. <i>Vaccine</i> , 2019 , 37, 4401-4406	4.1	7
8	Terminal Effector CD8 T Cells Defined by an IKZF2IL-7R Transcriptional Signature Express FcRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2019 , 203, 2210-2221	5.3	13
7	Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8 T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection. <i>ImmunoHorizons</i> , 2018 , 2, 172-184	2.7	4
6	Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-Infection. <i>Frontiers in Immunology</i> , 2018 , 9, 2174	8.4	13
5	Prospects for induction of CD8 T cell-mediated immunity to Zika virus infection by yellow fever virus vaccination. <i>Journal of Internal Medicine</i> , 2017 , 282, 206-208	10.8	5
4	NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection. <i>Journal of Immunology</i> , 2016 , 197, 2762-71	5.3	27
3	Specificity and dynamics of effector and memory CD8 T cell responses in human tick-borne encephalitis virus infection. <i>PLoS Pathogens</i> , 2015 , 11, e1004622	7.6	25
2	The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education. <i>Journal of Immunology</i> , 2015 , 195, 3262-72	5.3	41
1	Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. <i>Journal of Immunology</i> , 2013 , 190, 2150-8	5.3	80